Advertisement

Sports Medicine

, Volume 48, Issue 4, pp 971–989 | Cite as

Is Platelet-Rich Plasma (PRP) Effective in the Treatment of Acute Muscle Injuries? A Systematic Review and Meta-Analysis

  • Alberto Grassi
  • Francesca Napoli
  • Iacopo RomandiniEmail author
  • Kristian Samuelsson
  • Stefano Zaffagnini
  • Christian Candrian
  • Giuseppe Filardo
Systematic Review

Abstract

Background

Muscle lesions account for one-third of sport-related injuries, thus representing a substantial problem for both players and their teams. The use of platelet-rich plasma (PRP) injections is rapidly growing in clinical practice, prompted by an unmet clinical need with a large commercial market. However, after early reports of positive preliminary experience, higher quality studies recently questioned the real benefit provided by PRP injections to promote muscle healing and return to sport.

Objective

To evaluate the effect of platelet-rich plasma (PRP) injections on outcomes following acute muscle injuries.

Design

Meta-analysis of randomized, controlled trials (RCTs), Level I.

Data sources

PubMed (MEDLINE), Cochrane (CENTRAL), Web of Science, clinicaltrials.gov, who.int, isrctn.com, greylit.org, opengrey.eu.

Eligibility criteria

RCTs investigating the effect of PRP for the treatment of acute muscle injuries against at least one control group including patients treated with placebo injection or physical therapy. The outcomes evaluated were time to return to sport, re-injuries, complications, pain, muscle strength, range of motion (ROM)/flexibility, muscle function, and imaging.

Results

Six studies, involving 374 patients, were included in the meta-analysis. The time to return to sport evaluated in all six studies was significantly shorter in patients treated with PRP (mean difference = − 7.17 days). However, if only the double-blind studies (n = 2) or studies including only hamstring injuries (n = 3) were considered, non-significant differences were found. Re-injuries (relative risk = − 0.03) and complications (relative risk = 0.01) were also similar between the two groups (p > 0.05), nor were any substantial differences found regarding pain, muscle strength, ROM/flexibility, muscle function, and imaging. The performance bias was high risk due to the lack of patient blinding in four studies. The quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) was therefore low or very low.

Conclusions

The promising biological rationale, the positive preclinical findings, and the successful early clinical experience of PRP injections are not confirmed by the recent high-level RCTs. Therefore any benefit in terms of pain, function, return to sport, and recurrence using PRP injections for the treatment of acute muscle injuries is not supported. Due to the bias in the studies, the heterogeneity of the findings, and the limited sample size, the evidence should be considered to be of low or very low quality.

Notes

Author Contributions

Alberto Grassi, Francesca Napoli and Iacopo Romandini performed a database search, reviewed the articles and were responsible for data collection. Alberto Grassi performed an analysis of the results. Giuseppe Filardo and Alberto Grassi wrote the paper and critically evaluated the results. Kristian Samuelsson, Stefano Zaffagnini, and Christian Candrian critically reviewed and edited the manuscript.

Compliance with Ethical Standards

Funding

No sources of funding were used to assist in the preparation of this article.

Conflict of interest

Alberto Grassi, Francesca Napoli, Iacopo Romandini, Kristian Samuelsson and Christian Candrian declare that they have no conflicts of interest relevant to the content of this review. Giuseppe Filardo has worked in the platelet-rich plasma field for the past 10 years with no sponsorship. Recently, his institution received support for studying injective agents in osteoarthritis (not in a muscle-related field). This author declares no personal conflicts of interest of direct relevance to the content of this review. Stefano Zaffagnini receives personal fees from Smith and Nephew and DePuy, outside this work, and declares no conflicts of interest relevant to the content of this review.

References

  1. 1.
    Ekstrand J, Hagglund M, Walden M. Epidemiology of muscle injuries in professional football (soccer). Am J Sports Med. 2011;39(6):1226–32.CrossRefPubMedGoogle Scholar
  2. 2.
    Orchard J, Best TM, Verrall GM. Return to play following muscle strains. Clin J Sport Med. 2005;15(6):436–41.CrossRefPubMedGoogle Scholar
  3. 3.
    Heiderscheit BC, Sherry MA, Silder A, et al. Hamstring strain injuries: recommendations for diagnosis, rehabilitation, and injury prevention. J Orthop Sports Phys Ther. 2010;40(2):67–81.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ueblacker P, Haensel L, Mueller-Wohlfahrt HW. Treatment of muscle injuries in football. J Sports Sci. 2016;34(24):2329–37.CrossRefPubMedGoogle Scholar
  5. 5.
    Assis L, Moretti AI, Abrahao TB, et al. Low-level laser therapy (808 nm) contributes to muscle regeneration and prevents fibrosis in rat tibialis anterior muscle after cryolesion. Lasers Med Sci. 2013;28(3):947–55.CrossRefPubMedGoogle Scholar
  6. 6.
    Ms AH, Mohamed Ali MR, Yusof A, et al. Platelet-rich plasma injections for the treatment of hamstring injuries: a randomized controlled trial. Am J Sports Med. 2014;42(10):2410–8.CrossRefGoogle Scholar
  7. 7.
    Creaney L, Hamilton B. Growth factor delivery methods in the management of sports injuries: the state of play. Br J Sports Med. 2008;42(5):314–20.CrossRefPubMedGoogle Scholar
  8. 8.
    Cole BJ, Seroyer ST, Filardo G, et al. Platelet-rich plasma: where are we now and where are we going? Sports Health. 2010;2(3):203–10.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Filardo G, Kon E, Roffi A, et al. Platelet-rich plasma: why intra-articular? A systematic review of preclinical studies and clinical evidence on PRP for joint degeneration. Knee Surg Sports Traumatol Arthrosc. 2015;23(9):2459–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Cavallo C, Roffi A, Grigolo B, et al. Platelet-rich plasma: the choice of activation method affects the release of bioactive molecules. Biomed Res Int. 2016;2016:6591717.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Filardo G, Di Matteo B, Kon E, et al. Platelet-rich plasma in tendon-related disorders: results and indications. Knee Surg Sports Traumatol Arthrosc. 2016.  https://doi.org/10.1007/s00167-016-4261-4.Google Scholar
  12. 12.
    DeLong JM, Russell RP, Mazzocca AD. Platelet-rich plasma: the PAW classification system. Arthroscopy. 2012;28(7):998–1009.CrossRefPubMedGoogle Scholar
  13. 13.
    Torricelli P, Fini M, Filardo G, et al. Regenerative medicine for the treatment of musculoskeletal overuse injuries in competition horses. Int Orthop. 2011;35(10):1569–76.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27(3):158–67.CrossRefPubMedGoogle Scholar
  15. 15.
    Reurink G, Goudswaard GJ, Moen MH, et al. Rationale, secondary outcome scores and 1-year follow-up of a randomised trial of platelet-rich plasma injections in acute hamstring muscle injury: the Dutch Hamstring Injection Therapy study. Br J Sports Med. 2015;49(18):1206–12.CrossRefPubMedGoogle Scholar
  16. 16.
    Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Higgins JPTAD, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). London: The Cochrane Collaboration; 2011.Google Scholar
  18. 18.
    Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.CrossRefPubMedGoogle Scholar
  19. 19.
    Higgins JPTDJ, Altman DG. Special topics in statistics. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. London: The Cochrane Collaboration; 2011.Google Scholar
  20. 20.
    Deeks JJHJ, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). London: The Cochrane Collaboration; 2011.Google Scholar
  21. 21.
    Ms AH, Mohamed Ali MR, Yusof A, et al. Platelet-rich plasma (PRP): an adjuvant to hasten hamstring muscle recovery. A randomized controlled trial protocol (ISCRTN66528592). BMC Musculoskelet Disord. 2012;13:138.CrossRefGoogle Scholar
  22. 22.
    Reurink G, Goudswaard GJ, Moen MH, et al. Platelet-rich plasma injections in acute muscle injury. N Engl J Med. 2014;370(26):2546–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Hamilton B, Tol JL, Almusa E, et al. Platelet-rich plasma does not enhance return to play in hamstring injuries: a randomised controlled trial. Br J Sports Med. 2015;49(14):943–50.CrossRefPubMedGoogle Scholar
  24. 24.
    Bubnov R, Yevseenko V, Semeniv I. Ultrasound guided injections of platelets rich plasma for muscle injury in professional athletes. Comparative study. Med Ultrason. 2013;15(2):101–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Martinez-Zapata MJ, Orozco L, Balius R, et al. Efficacy of autologous platelet-rich plasma for the treatment of muscle rupture with haematoma: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Blood Transfus. 2016;14(2):245–54.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Rossi LA, Molina Romoli AR, Bertona Altieri BA, et al. Does platelet-rich plasma decrease time to return to sports in acute muscle tear? A randomized controlled trial. Knee Surg Sports Traumatol Arthrosc. 2016.  https://doi.org/10.1007/s00167-016-4129-7.Google Scholar
  27. 27.
    Serner A, van Eijck CH, Beumer BR, et al. Study quality on groin injury management remains low: a systematic review on treatment of groin pain in athletes. Br J Sports Med. 2015;49(12):813.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Drezner JA. Practical management: hamstring muscle injuries. Clin J Sport Med. 2003;13(1):48–52.CrossRefPubMedGoogle Scholar
  29. 29.
    Almekinders LC, Gilbert JA. Healing of experimental muscle strains and the effects of nonsteroidal antiinflammatory medication. Am J Sports Med. 1986;14(4):303–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Huard J, Li Y, Fu FH. Muscle injuries and repair: current trends in research. J Bone Joint Surg Am. 2002;84(5):822–32.CrossRefPubMedGoogle Scholar
  31. 31.
    Li H, Hicks JJ, Wang L, et al. Customized platelet-rich plasma with transforming growth factor beta1 neutralization antibody to reduce fibrosis in skeletal muscle. Biomaterials. 2016;87:147–56.CrossRefPubMedGoogle Scholar
  32. 32.
    Sherry MA, Best TM. A comparison of 2 rehabilitation programs in the treatment of acute hamstring strains. J Orthop Sports Phys Ther. 2004;34(3):116–25.CrossRefPubMedGoogle Scholar
  33. 33.
    Filardo G, Kon E. PRP: product Rich in Placebo? Knee Surg Sports Traumatol Arthrosc. 2016;24(12):3702–3.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.II Clinic Rizzoli Orthopaedic InstituteBolognaItaly
  2. 2.EOC-Regional Hospital of LuganoLuganoSwitzerland
  3. 3.NABI LaboratoryRizzoli Orthopaedic InstituteBolognaItaly
  4. 4.Department of Orthopaedics, Institute of Clinical Sciences, The Sahlgrenska AcademyUniversity of GothenburgGothenburgSweden

Personalised recommendations